Company Overview
Verastem, Inc. operates as a development-stage biopharmaceutical company dedicated to the research and development of therapeutic agents for cancer treatment within the United States market. The company functions within the broader Healthcare sector, specifically specializing in the Biotechnology industry, which focuses on the discovery and creation of new biological entities to address unmet medical needs. Its operational scale is defined by a market capitalization of $483.53M, an annual revenue of $30.91M over the trailing twelve months, and an employee base of 102 individuals. These financial metrics indicate that the company maintains a significant market valuation relative to its current revenue stream, suggesting that the market places a high premium on its pipeline of drug candidates, particularly Avutometinib, rather than on its immediate cash-flow generation capabilities.
Financial Health
The company reported a revenue of $30.91M for the trailing twelve months, yet this income was insufficient to cover its operational costs, resulting in a net income of $-209,471,008 and an EBITDA of $-169,400,992. The substantial gap between the positive revenue figure and the deeply negative net income reveals a cost structure characterized by high research and development expenses or other significant operational outflows typical of early-stage biotechnology firms. Furthermore, the free cash flow stands at $-82,332,872, which indicates a consistent burn rate that limits the company's current financial flexibility and necessitates ongoing capital raising efforts to sustain operations. Profitability metrics reflect this challenging environment, with a gross margin of 85.1% demonstrating efficient production or low cost of goods sold, contrasted sharply by an operating margin of -236.5% and a profit margin of 0.0%, both of which signal that overhead costs and R&D expenditures are consuming nearly all operating revenue. The balance sheet presents a leveraged position, holding $204.99M in cash against $87.17M in debt, supported by a debt-to-equity ratio of 152.40, which implies a reliance on equity financing rather than debt to fund its expansion. Despite the high debt relative to equity, the current ratio of 3.09 suggests robust short-term liquidity, indicating that the company possesses more than three times the current assets necessary to cover its current liabilities. Finally, the return on equity of -1480.2% and return on assets of -61.1% reveal that management is currently generating negative returns on the capital invested by shareholders and creditors, a common characteristic for companies in the development phase where capital is deployed for future potential rather than current profit generation.
Valuation Assessment
Valuation multiples for Verastem, Inc. reflect its status as a pre-profitability entity, with a trailing P/E ratio of N/A and a forward P/E of -4.65. The negative forward P/E implies that the market expects earnings to remain negative in the near term, rendering traditional price-to-earnings comparisons ineffective for assessing current value. The price-to-book ratio is calculated at 7.48, indicating that the stock trades at a significant premium over its net asset value, which is typical for biotechnology firms where intellectual property and pipeline potential outweigh current book value. Alternative valuation metrics such as the price-to-sales ratio of 15.64 and an EV/EBITDA of -2.17 further underscore that investors are pricing the company based on future revenue potential and market share acquisition rather than existing earnings power. In terms of trading range, the stock has experienced significant volatility within the past year, with a 52-week high of $11.25 and a 52-week low of $4.01. Assuming a trading price near the lower end of this spectrum, the stock is currently trading well below its 52-week high, reflecting the speculative nature of its asset class. The beta value of 0.40 indicates that the stock's price volatility is substantially lower than that of the broader market, suggesting it may move less dramatically than large-cap equities during periods of general market fluctuation.
Growth & Income
Growth metrics for the company are listed as N/A for both revenue growth year-over-year and earnings growth year-over-year, as these periods lack comparable historical data due to the company's recent establishment or lack of prior reporting history. Consequently, it is not possible to determine whether earnings are growing faster or slower than revenue using these specific figures, as the baseline for comparison does not exist in the available financial records. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means the entity retains all generated cash to fund its research and development activities rather than distributing income to shareholders. This strategy of reinvesting earnings into growth rather than paying dividends is a standard approach for development-stage biopharmaceutical companies that prioritize capital allocation toward clinical trials and commercialization over immediate shareholder returns. The overall growth and income profile is therefore defined by a complete reliance on capital appreciation driven by pipeline progress rather than dividend income or established earnings growth.